Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813892 | 0.75 | NR3C1 (0.53) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4417984 | 0.75 | NR3C1 (0.42) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28261345 | 0.73 | ALDH1A1 (0.39) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30828480 | 0.73 | MYB (0.44) | NR3C1PTAFR | |
| SCHEMBL14535459 | 0.70 | NR3C1 (0.44) | NR3C1PTAFRL3MBTL1 | |
| SCHEMBL30543464 | 0.70 | NR3C1 (0.44) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL11665700 | 0.70 | BRD4 (0.42) | NR3C1PTAFRL3MBTL1 | |
| SCHEMBL1494013 | 0.69 | NR3C1 (0.64) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7055800 | 0.68 | PDE4A (0.56) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| Ammonia Solution, Strong SCHEMBL7288975 | 0.68 | NR3C1 (0.62) | NR3C1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | BIOVITRUM AB (SE) | 2007-05-31 | — | — | US | disclosed |
| WO-2004054996-A1 | NEW SUBSTITUTED 1-PHENYL-TETRAHYDRONAPHTALENE DERIVATIVES AND THEIR USE AS INHIBITORS OF IGF-1 RECEPTOR | BIOVITRUM AB (SE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123491-A1 | Podophyllotoxin derivatives as igf-1r inhibitors | IGF1R, IGFBP1, INSR | NR3C1 1734/4885PDE4A 2905/4885PDE4B 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.